Skip to main content
. 2021 Jul 8;9(7):e002267. doi: 10.1136/jitc-2020-002267

Figure 2.

Figure 2

The combination of N-803 and dinutuximab significantly enhanced in vitro cytotoxicity of exPBNK with enhanced perforin and IFN-γ release against OS, NB and GBM cells. Expanded NK cells were isolated for invitro cytotoxicity assays against OS, NB and GBM cells. (A) The combination of exPBNK cells with N-803 +dinutiximab significantly killed U2OS (OS), M059K (GBM) and SKNFI (NB) cells as compared with exPBNK cells with single agent (IgG, N-803 or dinutuximab) at E:T ratios=1:1 or 3:1 at day 3. The ‘RAMPs’ stand for the E:T ratios at 1:1 and 3:1. (B) The combination of exPBNK cells with N-803+ dinutiximab significantly enhanced perforin release from exPBNK cells as compared with exPBNK cells with single agent (IgG, N-803 or dinutuximab) at E:T ratios=3:1. (C) The combination of exPBNK cells with N-803+ dinutiximab significantly enhanced IFN-γ release from exPBNK cells as compared with exPBNK cells with single agent (IgG, N-803 or dinutuximab) at E:T ratios=3:1. *P<0.05, **p<0.01, ***p<0.001, Dinut=dinutuximab. Data were presented as mean±SEM from four independent experiments. OS=U2OS cell line, GBM=M059K cell line, and NB=SKNFI cell line. E:T, effector-to-target; exPBNK, expanded peripheral blood natural killer cell; GBM, glioblastoma multiforme; IFN-γ, interferon-γ; NK, natural killer; ns, not significant; OS, osteosarcoma; NB, neuroblastoma.